Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01177 SINO BIOPHARM
RTNominal up2.740 +0.060 (+2.239%)
Others

18/07/2019 09:49

Sino Biopharm (01177) anti-tumour drug gets approval

[ET Net News Agency, 18 July 2019] Sino Biopharmaceutical Limited (01177) said the
anti-tumour drug "Abiraterone Acetate Tablet" developed by Chia Tai - Tianqing
Pharmaceutical Group Co. Ltd., a subsidiary of the company, has obtained approval for drug
registration granted by the National Medical Products Administration of the People's
Republic of China. The Abiraterone Acetate Tablet developed by the group was the second of
its type to obtain approval for drug registration in China.
Abiraterone is a selective, irreversible steroid inhibitor of CYP17A1. It prevents
testosterone synthesis in testes, adrenal glands and tumours by inhibiting enzyme
activity. It is applied in combination with prednisone to treat metastatic
castration-resistant prostate cancer. (RC)

Back to Others

Remark: Real time quote last updated: 25/04/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.